Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on July 29, 2008
JNCI Journal of the National Cancer Institute 2008 100(15):E1; doi:10.1093/jnci/djn212
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/15/E1    most recent
djn212v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Herbst, C.
Right arrow Articles by Engert, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herbst, C.
Right arrow Articles by Engert, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2008.

ONLINE COMMENTARY

Eighth Biannual Report of the Cochrane Haematological Malignancies Group—Focus on Chronic Lymphatic Leukemia

Christine Herbst, Ina Monsef, Nicole Skoetz, Andreas Engert

Affiliations of authors: Cochrane Haematological Malignancies Group, First Department of Internal Medicine 1 (CH, IM, NS) and First Department of Internal Medicine 1, University Hospital of Cologne (AE), Cologne, Germany

Correspondence to: Christine Herbst, MD,MPH, Cochrane Haematological Malignancies Group, Department of Internal Medicine 1, University Hospital of Cologne, Kerpener Strasse 62, D-50924 Cologne, Germany (e-mail: christine.herbst@uk-koeln.de).

The first 150 words of the full text of this article appear below.


   Introduction
 
The Cochrane Haematological Malignancies Group, based at Cologne, Germany, searches continuously and systematically for clinical trials in the field of hemato-oncology. Randomized controlled trials (RCTs) are identified through electronic search of Medline (OVID gateway) using a broad search filter that covers all topics in hemato-oncology combined with a highly sensitive search filter for randomized studies (Cochrane handbook for systematic reviews of interventions 4.2.5; Appendix 5b.2—phase 1 and phase 2; The Cochrane Collaboration 2006 [updated September 2006] http://www.cochrane.org/resources/handbook/Handbook4.2.6Sep2006.pdf). The search presented here covers publications from April 2007 to December 2007.

In these 9 months, 79 controlled clinical trials (RCTs and nonrandomized clinical trials) were published on therapeutic interventions in several hematologic malignancies (eg, Hodgkin and non-Hodgkin lymphoma, multiple myeloma, and acute and chronic leukemia).

In our present summary of key features of recent RCTs, we focus on chronic lymphatic leukemia. Four recently published trials in patients with chronic lymphocytic leukemia . . . [Full Text of this Article]


   Published Trials in Patients With CLL
 
First-Line Therapy of CLL: Chlorambucil, Fludarabine, or Fludarabine Plus Cyclophosphamide

Clinical background.

Contribution.

Implication for practice.

Most interesting feature.


   Quality of Life Using Fludarabine Alone or Fludarabine Plus Cyclophosphamide as First-Line Therapy of CLL
 

   Contribution.
 

   Most interesting feature.
 

   First-Line Therapy for CLL: Alemtuzumab Compared With Chlorambucil
 

   Clinical background.
 

   Contribution.
 

   Implications for practice.
 

   Most interesting feature.
 

   Treatment of Relapsed CLL
 

   Clinical background.
 

   Contribution.
 

   Implications for practice.
 

   Most interesting feature.
 

   Methodological Issues: Health-Related Quality of Life
 

   Other Interesting Trials
 

   The Cochrane Library
 
New Reviews

New Protocols


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?